Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp. > This is a horrible investment.....
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by TraderBenon Feb 28, 2017 10:56am
79 Views
Post# 25904916

RE:RE:RE:RE:RE:RE:RE:This is a horrible investment.....

RE:RE:RE:RE:RE:RE:RE:This is a horrible investment.....CytochromeP:  You are new here right?

Target price/base case

Our $1.00 price target is based on the average of our EV/EBITDA valuation and DCF analysis. Applying a 7.25x multiple to our 2018 Adj. EBITDA forecast of ~$423MM generates a value of $1.05. Our DCF value (12.5% WACC and a -2% terminal growth rate) equates to $0.88. The average of our EV/EBITDA and DCF values is $0.97, rounded to our $1.00 price target. T  Our $0 downside scenario utilizes a 7.2x multiple on 2018E Adj. EBITDA of $418MM (prev. $422MM), generating a value of $0.00. 


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities